[바이오사 리포트] SK바사, 적자 감수한 R&D…반등 자산 PCV21

SK Bioscience is strategically pivoting from COVID-19 windfall profits to long-term vaccine innovation, accepting near-term losses to fund PCV21 and a diversified pipeline. The 2029 global launch target for PCV21 represents a critical bet that could establish the company as a major player in the pneumococcal vaccine market beyond competitors like Pfizer. This reflects a broader industry shift where sustained R&D investment and pipeline diversification are becoming essential competitive advantages in the post-pandemic era.